ISSN 1725-2423

Official Journal of the European Union

C 115

Volume 50

English edition

Information and Notices

25 May 2007

Contents

EN

[1] Text with EEA relevance

(Continued overleaf)

EN

[1] Text with EEA relevance

II

(Information)

INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES

COMMISSION

Non-opposition to a notified concentration

(Case COMP/M.4638 — CERP/Sanacorp/Millenium)

(Text with EEA relevance)

(2007/C 115/01)

On 4 May 2007, the Commission decided not to oppose the above notified concentration and to declare it compatible with the common market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004. The full text of the decision is available only in English and will be made public after it is cleared of any business secrets it may contain. It will be available:

— from the Europa competition website (http://ec.europa.eu/comm/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

— in electronic form on the EUR-Lex website under document number 32007M4638. EUR-Lex is the on-line access to European law. (http://eur-lex.europa.eu)

IV

(Notices)

NOTICES FROM EUROPEAN UNION INSTITUTIONS AND BODIES

COMMISSION

Euro exchange rates ([1])

24 May 2007

(2007/C 115/02)

1 euro =

	Currency	Exchange rate		Currency	Exchange rate
USD	US dollar	1,3448	RON	Romanian leu	3,2725
JPY	Japanese yen	163,20	SKK	Slovak koruna	33,787
DKK	Danish krone	7,4514	TRY	Turkish lira	1,7915
GBP	Pound sterling	0,67670	AUD	Australian dollar	1,6351
SEK	Swedish krona	9,1957	CAD	Canadian dollar	1,4552
CHF	Swiss franc	1,6508	HKD	Hong Kong dollar	10,5208
ISK	Iceland króna	83,62	NZD	New Zealand dollar	1,8453
NOK	Norwegian krone	8,1055	SGD	Singapore dollar	2,0538
BGN	Bulgarian lev	1,9558	KRW	South Korean won	1 252,61
CYP	Cyprus pound	0,5832	ZAR	South African rand	9,5581
CZK	Czech koruna	28,252	CNY	Chinese yuan renminbi	10,2903
EEK	Estonian kroon	15,6466	HRK	Croatian kuna	7,3160
HUF	Hungarian forint	249,47	IDR	Indonesian rupiah	11 753,55
LTL	Lithuanian litas	3,4528	MYR	Malaysian ringgit	4,5582
LVL	Latvian lats	0,6962	PHP	Philippine peso	62,143
MTL	Maltese lira	0,4293	RUB	Russian rouble	34,8270
PLN	Polish zloty	3,8000	THB	Thai baht	44,222

([1]) *Source:* reference exchange rate published by the ECB.

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 April 2007 to 30 April 2007

(Published pursuant to Article 13 or Article 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council [1]*)*

(2007/C 115/03)

— Issuing of a marketing authorization (Article 13 of Regulation (EC) No 726/2004): Accepted

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorization	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
20.4.2007	TOVIAZ	fesoterodine	Schwarz Pharma AG Alfred-Nobel Straße 10 D-40789 Monheim	EU/1/07/386/001-010	Prolonged-release tablets	G04B D11	24.4.2007
20.4.2007	Docetaxel Winthrop	docetaxel	Aventis Pharma S.A. 20, avenue Raymond Aron F-92165 Antony Cedex	EU/1/07/384/001-002	Concentrate and solvent for solution for infusion	L01CD02	24.4.2007
23.4.2007	Advagraf	Tacrolimus	Astellas Pharma GmbH Neumarkter Str. 61 D-81673 München	EU/1/07/387/001-008	Prolonged release hard capsules	L04AA05	25.4.2007
24.4.2007	Sebivo	telbivudine	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	EU/1/07/388/001	Film-coated tablet	J05AF11	26.4.2007

[1] OJ L 136, 30.4.2004, p. 1.

— **Modification of a marketing authorization (Article 13 of Regulation (EC) No 726/2004): Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
2.4.2007	Dynepo	Shire Pharmaceutical Contracts Ltd Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom	EU/1/02/211/001-005 EU/1/02/211/010-012	4.4.2007
2.4.2007	Prevenar	Wyeth-Lederle Vaccines S.A. Rue du Bosquet 15 B-1348 Louvain-La-Neuve	EU/1/00/167/001-007	4.4.2007
2.4.2007	Xigris	Eli Lilly Nederland B.V. Grootslag 1-5 3991 RA Houten Nederland	EU/1/02/225/001-002	4.4.2007
2.4.2007	AZILECT	Teva Pharma GmbH Kandelstraße 10 D-79199 Kirchzarten	EU/1/04/304/001-007	4.4.2007
2.4.2007	Enbrel	Wyeth Europa Limited Huntercombe Lane South Taplow Maidenhead Berkshire SL6 0PH United Kingdom	EU/1/99/126/013-018	4.4.2007
4.4.2007	Cerezyme	Genzyme Europe B.V. Gooimeer 10 1411 DD Naarden Nederland	EU/1/97/053/001-005	11.4.2007
11.4.2007	Panretin	Ligand Pharmaceuticals UK Ltd Innovis House 108 High Street Crawley West Sussex RH10 1BB United Kingdom Eisai Ltd 3 Shortlands London W6 8EE United Kingdom	EU/1/00/149/001	13.4.2007 13.4.2007
11.4.2007	TARGRETIN	Ligand Pharmaceuticals UK Ltd Innovis House 108 High Street Crawley West Sussex RH10 1BB United Kingdom Eisai Ltd 3 Shortlands London W6 8EE United Kingdom	EU/1/01/178/001	13.4.2007 13.4.2007
13.4.2007	Infanrix Penta	GlaxoSmithKline Biologicals s.a. rue de l'Institut 89 B-1330 Rixensart	EU/1/00/153/001-010	17.4.2007
13.4.2007	Infanrix Hexa	GlaxoSmithKline Biologicals s.a. rue de l'Institut 89 B-1330 Rixensart	EU/1/00/152/001-018	17.4.2007

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
13.4.2007	Foscan	Biolitec pharma Ltd United Drug House Magna Drive Dublin 24 Ireland	EU/1/01/197/001-002	18.4.2007
13.4.2007	Revatio	Pfizer Ltd Ramsgate Road Sandwich Kent CT 13 9NJ United Kingdom	EU/1/05/318/001	17.4.2007
13.4.2007	Glivec	Novartis Europharm Limited Wimblehurst Road Horsham West Sussex RH12 5AB United Kingdom	EU/1/01/198/001-013	17.4.2007
17.4.2007	Cystagon	Orphan Europe Immeuble 'Le Guillaumet' F-92046 Paris La Défense	EU/1/97/039/001-004	19.4.2007
17.4.2007	Teslascan	GE Healthcare AS Nycoveien 1-2 P.O.Box 4220 Nydalen N-0401 Oslo	EU/1/97/040/001-002	19.4.2007
17.4.2007	Dynepo	Shire Pharmaceutical Contracts Ltd Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom	EU/1/02/211/001-005 EU/1/02/211/010-012	19.4.2007
20.4.2007	Quixidar	Glaxo Group Ltd Greenford Middlesex UB6 0NN United Kingdom	EU/1/02/207/001-020	24.4.2007
20.4.2007	Arixtra	Glaxo Group Ltd Greenford Middlesex UB6 0NN United Kingdom	EU/1/02/206/001-020	24.4.2007
20.4.2007	Omnitrope	Sandoz GmbH Biochemiestraße 10 A-6250 Kundl	EU/1/06/332/004-006	24.4.2007
23.4.2007	Azomyr	Schering Plough Europe Rue de Stalle 73 B-1180 Bruxelles Stallestraat 73 B-1180 Brussel	EU/1/00/157/035-067	25.4.2007
23.4.2007	Neoclarityn	Schering Plough Europe Rue de Stalle 73 B-1180 Bruxelles Stallestraat 73 B-1180 Brussel	EU/1/00/161/035-067	25.4.2007
23.4.2007	Aerius	Schering Plough Europe Rue de Stalle 73 B-1180 Bruxelles Stallestraat 73 B-1180 Brussel	EU/1/00/160/037-069	25.4.2007

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
23.4.2007	Temodal	Schering Plough Europe Rue de Stalle 73 B-1180 Bruxelles Stallestraat 73 B-1180 Brussel	EU/1/98/096/009-012	25.4.2007
23.4.2007	Dynastat	Pfizer Ltd Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom	EU/1/02/209/001-008	25.4.2007
23.4.2007	M-M-RVAXPRO	Sanofi Pasteur MSD SNC 8, rue Jonas Salk F-69007 Lyon	EU/1/06/337/001-013	25.4.2007
23.4.2007	Avastin	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom	EU/1/04/300/001-002	25.4.2007
23.4.2007	Kinzalkomb	Bayer HealthCare AG D-51368 Leverkusen	EU/1/02/214/001-010	25.4.2007
23.4.2007	MicardisPlus	Boehringer Ingelheim International GmbH Binger Straße 173 D-55216 Ingelheim am Rhein	EU/1/02/213/001-016	25.4.2007
24.4.2007	Macugen	Pfizer Ltd Ramsgate Road Sandwich Kent CT 13 9NJ United Kingdom	EU/1/05/325/001	26.4.2007
24.4.2007	Kineret	Amgen Europe B.V. Minervum 7061 4817 ZK Breda Nederland	EU/1/02/203/001-004	26.4.2007
24.4.2007	Truvada	Gilead Sciences International Limited Cambridge CB21 6G United Kingdom	EU/1/04/305/001	26.4.2007
24.4.2007	Herceptin	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom	EU/1/00/145/001	26.4.2007
24.4.2007	NovoMix	Novo Nordisk A/S Novo Allé DK-2880 Bagsvaerd	EU/1/00/142/004-005 EU/1/00/142/009-010	26.4.2007
24.4.2007	Aldara	Laboratoires 3M Santé Boulevard de l'Oise F-95029 Cergy Pontoise Cedex	EU/1/98/080/001	26.4.2007

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
24.4.2007	DaTSCAN	GE Healthcare Limited Little Chalfont Bucks HP7 9NA United Kingdom	EU/1/00/135/001-002	26.4.2007
25.4.2007	Bondenza	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom	EU/1/03/266/001-006	30.4.2007
25.4.2007	Bonviva	Roche Registration Limited 6 Falcon Way Shire Park Welwyn Garden City AL7 1TW United Kingdom	EU/1/03/265/001-006	30.4.2007
25.4.2007	Xigris	Eli Lilly Nederland B.V. Grootslag 1-5 3991 RA Houten Nederland	EU/1/02/225/001-002	27.4.2007
25.4.2007	Emtriva	Gilead Sciences International Limited Cambridge CB21 6GT United Kingdom	EU/1/03/261/001-003	27.4.2007
26.4.2007	Baraclude	Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UD8 1DH United Kingdom	EU/1/06/343/001-005	30.4.2007
26.4.2007	Lysodren	Laboratoire HRA Pharma 15, rue Béranger F-75003 Paris	EU/1/04/273/001	30.4.2007
26.4.2007	Champix	Pfizer Ltd Ramsgate Road Sandwich Kent CT 13 9NJ United Kingdom	EU/1/06/360/001-011	30.4.2007
26.4.2007	REYATAZ	Bristol-Myers Squibb Pharma EEIG Uxbridge Business Park Sanderson Road Uxbridge UD8 1DH United Kingdom	EU/1/03/267/001-007	30.4.2007

— **Issuing of a marketing authorization (Article 38 of Regulation (EC) No 726/2004): Accepted**

Date of the decision	Name of the medicinal product	INN (International Non-Proprietary Name)	Holder of the marketing authorization	Number of the entry in the Community Register	Pharmaceutical form	ATC code (Anatomical Therapeutic Chemical Code)	Date of notification
13.4.2007	Slentrol	Dirlotapide	Pfizer Ltd Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom	EU/2/07/071/001-003	Oral solution	QA08AB91	17.4.2007

— **Modification of a marketing authorization (Article 38 of Regulation (EC) No 726/2004): Accepted**

Date of the decision	Name of the medicinal product	Holder of the marketing authorization	Number of the entry in the Community Register	Date of notification
20.4.2007	Metacam	Boehringer Ingelheim Vetmedica GmbH D-55216 Ingelheim am Rhein	EU/2/97/004/012-013 EU/2/97/004/026	24.4.2007
24.4.2007	Oxyglobin	Biopure Netherlands B.V. Drentestraat 24BG 1083HK Amsterdam Nederland	EU/2/99/015/001	26.4.2007

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Medicines Agency
7, Westferry Circus
Canary Wharf
London E14 4HB
United Kingdom

Summary of Community decisions on marketing authorizations in respect of medicinal products from 1 April 2007 to 30 April 2007

(Decisions taken pursuant to Article 34 of Directive 2001/83/EC [1] or Article 38 of Directive 2001/82/EC [2])

(2007/C 115/04)

— Issuing, maintenance or modification of a national marketing authorisation

Date of the decision	Name(s) of the medicinal product	Holder(s) of the marketing authorization	Member State concerned	Date of notification
13.4.2007	Alendronate Hexal	See Annex I	See Annex I	18.4.2007
13.4.2007	Gadovist	See Annex II	See Annex II	19.4.2007
13.4.2007	Gadograf	See Annex III	See Annex III	19.4.2007
17.4.2007	Dolovet	See Annex IV	See Annex IV	20.4.2007
17.4.2007	Suvaxyn Parvo E	See Annex V	See Annex V	20.4.2007
19.4.2007	Suvaxyn Ery	See Annex VI	See Annex VI	20.4.2007

— Suspension of a national marketing authorization

Date of the decision	Name(s) of the medicinal product	Holder(s) of the marketing authorization	Member State concerned	Date of notification
2.4.2007	Equimectin	See Annex VII	See Annex VII	3.4.2007
13.4.2007	Mefecur	See Annex VIII	See Annex VIII	19.4.2007
13.4.2007	Mefecomb	See Annex IX	See Annex IX	20.4.2007
13.4.2007	Mefelor	See Annex X	See Annex X	19.4.2007
13.4.2007	Mefesan	See Annex XI	See Annex XI	19.4.2007
13.4.2007	Metofelosan	See Annex XII	See Annex XII	20.4.2007
13.4.2007	Metoprolol/Felodipin 'YES'	See Annex XIII	See Annex XIII	18.4.2007

[1] OJ L 311, 28.11.2001, p. 67.
[2] OJ L 311, 28.11.2001, p. 1.

ANNEX I

LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, APPLICANT, MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES

Member State	Marketing Authorisation Holder	Applicant	Invented name Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Sweden	HEXAL A/S Kanalholmen 8-12 DK-2650 Hvidovre		Alendronat HEXAL	10 mg	Tablets	Oral use	10 mg per tablet
Belgium		HEXAL A/S Kanalholmen 8-12 DK-2650 Hvidovre	Alendronate Sandoz 10 mg tabletten	10 mg	Tablets	Oral use	10 mg per tablet
Denmark		HEXAL A/S Kanalholmen 8-12 DK-2650 Hvidovre	Alendonicht	10 mg	Tablets	Oral use	10 mg per tablet
Greece		HEXAL A/S Kanalholmen 8-12 DK-2650 Hvidovre	Forosa	10 mg	Tablets	Oral use	10 mg per tablet

ANNEX II

LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

Member State	Marketing Authorisation Holder	Invented name	Strength	Pharmaceutical Form	Route of administration
Austria	Schering Austria GmbH Wienerbergstraße 41 Euro Plaza-Gebäude F/PF45 A-1121 Wien	Gadovist	1 mmol/ml	Solution for injection	Intravenous use
Austria	Schering Austria GmbH Wienerbergstraße 41 Euro Plaza-Gebäude F/PF45 A-1121 Wien	Gadovist	1 mmol/ml	Solution for Injection in prefilled syringe	Intravenous use
Belgium	NV Schering S.A. J.E. Mommaertslaan, 14 B-1831 Machelen (Diegem)	Gadovist	1 mmol/ml	Solution for injection	Intravenous use
Belgium	NV Schering S.A. J.E. Mommaertslaan, 14 B-1831 Machelen (Diegem)	Gadovist	1 mmol/ml	Solution for Injection in prefilled syringe	Intravenous use
Denmark	Schering AG Müllerstr. 178 D-13342 Berlin-Mitte	Gadovist	1 mmol/ml	Solution for injection	Intravenous use
Denmark	Schering AG Müllerstr. 178 D-13342 Berlin-Mitte	Gadovist	1 mmol/ml	Solution for Injection in prefilled syringe	Intravenous use
Germany	Schering Deutschland GmbH Max-Dohrn-Strasse 10 D-10589 Berlin	Gadovist	1 mmol/ml	Solution for injection	Intravenous use
Germany	Schering Deutschland GmbH Max-Dohrn-Strasse 10 D-10589 Berlin	Gadovist	1 mmol/ml	Solution for Injection in prefilled syringe	Intravenous use
Greece	Schering Hellas SA 466 Irakliou Ave. & 12-14 Kyprou Str. Neo Iraklio GR-14122 Athens	Gadovist	1 mmol/ml	Solution for injection	Intravenous use
Greece	Schering Hellas SA 466 Irakliou Ave. &12-14 Kyprou Str. Neo Iraklio GR-14122 Athens	Gadovist	1 mmol/ml	Solution for Injection in prefilled syringe	Intravenous use
Spain	Schering España, S.A. c/ Mendez Alvaro, 55 E-28045 Madrid	Gadovist	1 mmol/ml	Solution for injection	Intravenous use
Spain	Schering España, S.A. c/ Mendez Alvaro, 55 E-28045 Madrid	Gadovist	1 mmol/ml	Solution for Injection in prefilled syringe	Intravenous use

Member State	Marketing Authorisation Holder	Invented name	Strength	Pharmaceutical Form	Route of administration
Finland	Schering Oy Pansiontie 47 Post Box 415 FIN-20101 Turku	Gadovist	1 mmol/ml	Solution for injection	Intravenous use
Finland	Schering Oy Pansiontie 47 Post Box 415 FIN-20101 Turku	Gadovist	1 mmol/ml	Solution for Injection in prefilled syringe	Intravenous use
France	Schering SA Z.I. Roubaix-Est rue de Toufflers BP 69 F-59452 Lys-Lez-Lannoy Cedex	Gadovist	1 mmol/ml	Solution for injection	Intravenous use
France	Schering SA Z.I. Roubaix-Est rue de Toufflers BP 69 F-59452 Lys-Lez-Lannoy Cedex	Gadovist	1 mmol/ml	Solution for Injection in prefilled syringe	Intravenous use
Ireland	HE Clissmann T/A Schering 72 Heather Road Dublin 18 Ireland	Gadovist	1 mmol/ml	Solution for injection	Intravenous use
Ireland	HE Clissmann T/A Schering 72 Heather Road Dublin 18 Ireland	Gadovist	1 mmol/ml	Solution for Injection in prefilled syringe	Intravenous use
Italy	Schering S.p.A. Via E. Schering, 21 I-20090 Segrate (MI)	Gadovist	1 mmol/ml	Solution for injection	Intravenous use
Italy	Schering S.p.A. Via E. Schering, 21 I-20090 Segrate (MI)	Gadovist	1 mmol/ml	Solution for Injection in prefilled syringe	Intravenous use
Luxembourg	NV Schering S.A. J.E. Mommaertslaan, 14 B-1831 Machelen (Diegem)	Gadovist	1 mmol/ml	Solution for injection	Intravenous use
Luxembourg	NV Schering S.A. J.E. Mommaertslaan, 14 B-1831 Machelen (Diegem)	Gadovist	1 mmol/ml	Solution for Injection in prefilled syringe	Intravenous use
Netherlands	Schering Nederland B.V Van Houten Industriepark 1 Postbus 116 1380 AC Weesp Nederland	Gadovist	1 mmol/ml	Solution for injection	Intravenous use
Netherlands	Schering Nederland B.V Van Houten Industriepark 1 Postbus 116 1380 AC Weesp Nederland	Gadovist	1 mmol/ml	Solution for Injection in prefilled syringe	Intravenous use
Norway	Schering AG Müllerstr. 178 D-13342 Berlin-Mitte	Gadovist	1 mmol/ml	Solution for injection	Intravenous use
Norway	Schering AG Müllerstr. 178 D-13342 Berlin-Mitte	Gadovist	1 mmol/ml	Solution for Injection in prefilled syringe	Intravenous use

Member State	Marketing Authorisation Holder	Invented name	Strength	Pharmaceutical Form	Route of administration
Portugal	Schering Lusitana, Lda Estrada Nacional 249, km 15 P.O. Box 16 P-2725-397 Mem Martins	Gadovist	1 mmol/ml	Solution for injection	Intravenous use
Sweden	Schering AG Müllerstr. 178 D-13342 Berlin-Mitte	Gadovist	1 mmol/ml	Solution for injection	Intravenous use
Sweden	Schering AG Müllerstr. 178 D-13342 Berlin-Mitte Allemagne	Gadovist	1 mmol/ml	Solution for Injection in prefilled syringe	Intravenous use
United Kingdom	Schering Health Care Limited The Brow Burgess Hill West Sussex RH1F 9NE United Kingdom	Gadovist	1 mmol/ml	Solution for injection	Intravenous use
United Kingdom	Schering Health Care Limited The Brow Burgess Hill West Sussex RH1F 9NE United Kingdom	Gadovist	1 mmol/ml	Solution for Injection in prefilled syringe	Intravenous use

ANNEX III

LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

Member State	Marketing Authorisation Holder	Invented name	Strength	Pharmaceutical Form	Route of administration
Germany	Schering Deutschland GmbH Max-Dohrn-Strasse 10 D-10589 Berlin	Gadograf	1 mmol/ml	Solution for injection	Intravenous use
Germany	Schering Deutschland GmbH Max-Dohrn-Strasse 10 D-10589 Berlin	Gadograf	1 mmol/ml	Solution for Injection in prefilled syringe	Intravenous use
Spain	Schering España, S.A. c/ Mendez Alvaro, 55 E-28045 Madrid	Gadograf	1 mmol/ml	Solution for injection	Intravenous use
Spain	Schering España, S.A. c/ Mendez Alvaro, 55 E-28045 Madrid	Gadograf	1 mmol/ml	Solution for Injection in prefilled syringe	Intravenous use

ANNEX IV

NAME, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ANIMAL SPECIES, ROUTES OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDER

Member State	Applicant or Marketing Authorisation Holder	Product invented name	Pharmaceutical form	Strength	Animal species	Frequency and route of administration	Recommended dose
Belgium, Czech Republic, Denmark, Spain, Finland, Italy, Luxembourg, The Netherlands, Norway, Poland and Slovakia	Vetcare Ltd. P. O. Box 99 FIN-24101 Salo	Dolovet vet 2,4 g	Powder	2.4g ketoprofen per sachet of 15g powder	Cattle (adult animals weighing about 600 kg)	One bag of 15g once daily for 1 — 3 days. The powder should be mixed with water e.g. in a bottle using ½ litres of water, shaked well and administered immediately per orally to an animal	One bag of 15g once daily for 1 — 3 days. This corresponds to 4mg ketoprofen per kg body weight
Austria and Hungary	As above	Rifen 2,4 g	As above	As above	As above	As above	As above

ANNEX V

NAME, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ANIMAL SPECIES, ROUTES OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDER

Member State	Marketing Authorisation Holder	Applicant	Product invented name	Pharmaceutic-al form	Strength	Animal species	Frequency and route of administration	Recomme-nded dose
Austria	Wyeth Lederle Pharma GmbH, Fort Dodge Waidhausengasse 19/9 A-1140 Vienna Contact: Dr. Attila Romváry Tel: +43 1 912 28 40 Fax: +43 1 911 51 00 Email: romvara@fdah.com	Wyeth Lederle Pharma GmbH, Fort Dodge	Suvaxyn Parvo/E	Emulsion for injection	— PPV inducing a HIA titre of at least 160 (in rabbits). — E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
Belgium	Fort Dodge Animal Health Holland C.J. van Houtenlaan 36 1381 CP Weesp The Netherlands Contact: Dr. Durk Stellingwerf Tel: (31-35) 699 33 72 Fax: (31-35) 699 33 80 Email: stellid@fdah.com	Fort Dodge Animal Health Holland	Suvaxyn Parvo/E	Emulsion for injection	— PPV inducing a HIA titre of at least 160 (in rabbits). — E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
France	Fort Dodge Santé Animale S.A. 24, Avenue Marcel Dassault BP 440 F-37204 Tours Cedex 3 Contact: Mr. Yves Dehon Tel: +33 2 4774 8979 Fax: +33 2 47748999 Email: dehony@ahp.com	Fort Dodge Santé Animale S.A.	Suvaxyn Parvo/E	Emulsion for injection	— PPV inducing a HIA titre of at least 160 (in rabbits). — E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml

Member State	Marketing Authorisation Holder	Applicant	Product invented name	Pharmaceutic-al form	Strength	Animal species	Frequency and route of administration	Recomme-nded dose
Germany	Fort Dodge Veterinär GmbH Adenauerstrasse 20 D-52146 Würselen Contact: Dr. Elisabeth Stangl Tel: (49-240) 545 42 16 Fax: (49-240) 545 44 61 Email: stangle@fdah.com	Fort Dodge Veterinär GmbH	Suvaxyn Parvo/E	Emulsion for injection	— PPV inducing a HIA titre of at least 160 (in rabbits). — E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
Greece	Wyeth Lederle Pharma GmbH, Fort Dodge Waidhausengasse 19/9 A-1140 Vienna Contact: Dr. Eusebio Uruburu Tel: (34-915) 98 13 44 Fax: (34-915) 97 24 34 Email: urubure@fdah.com	Wyeth Lederle Pharma GmbH, Fort Dodge	Suvaxyn Parvo/E	Emulsion for injection	— PPV inducing a HIA titre of at least 160 (in rabbits). — E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
Ireland	Fort Dodge Animal Health Limited Flanders Road Hedge End Southampton S030 4QH United Kingdom Contact: Dr. Germán Lastra Tel: (44-14) 89 77 42 21 Fax: (44-14) 89 77 42 51 Email: lastrag@fdah.com	Fort Dodge Animal Health Limited	Suvaxyn Parvo/E	Emulsion for injection	— PPV inducing a HIA titre of at least 160 (in rabbits). — E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml

Member State	Marketing Authorisation Holder	Applicant	Product invented name	Pharmaceutic-al form	Strength	Animal species	Frequency and route of administration	Recomme-nded dose
Luxembourg	Fort Dodge Animal Health Holland C.J. van Houtenlaan 36 1381 CP Weesp The Netherlands Contact: Dr. Durk Stellingwerf Tel: (31-35) 699 33 72 Fax: (31-35) 699 33 80 Email: stellid@fdah.com	Fort Dodge Animal Health Holland	Suvaxyn Parvo/E	Emulsion for injection	— PPV inducing a HIA titre of at least 160 (in rabbits). — E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
Netherlands	Fort Dodge Animal Health Holland C.J. van Houtenlaan 36 1381 CP Weesp The Netherlands Contact: Dr. Durk Stellingwerf Tel: (31-35) 699 33 72 Fax: (31-35) 699 33 80 Email: stellid@fdah.com	Fort Dodge Animal Health Holland	Suvaxyn Parvo/E	Emulsion for injection	— PPV inducing a HIA titre of at least 160 (in rabbits). — E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
Norway	Fort Dodge Veterinaria S.A. c/ Camprodón s/n 'La Riba' Vall de Bianya (Girona), Spain Contact: Dr. Germán Lastra Tel: +44 1489774221 Fax: +44 1489 774 251 Email: lastrag@fdah.com	Fort Dodge Veterinaria S.A.	Suvaxyn Parvo/E	Emulsion for injection	— PPV inducing a HIA titre of at least 160 (in rabbits). — E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml

Member State	Marketing Authorisation Holder	Applicant	Product invented name	Pharmaceutic-al form	Strength	Animal species	Frequency and route of administration	Recomme-nded dose
Sweden	Fort Dodge Animal Health Holland C.J. van Houtenlaan 36 1381 CP Weesp The Netherlands Contact: Dr. Germán Lastra Tel: +44 1489774221 Fax: +44 1489 774 251 Email: lastrag@fdah.com	Fort Dodge Animal Health Holland	Suvaxyn Parvo/E vet	Emulsion for injection	— PPV inducing a HIA titre of at least 160 (in rabbits). — E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
United Kingdom	Fort Dodge Animal Health Limited Flanders Road Hedge End Southampton S030 4QH United Kingdom Tel: (44-14) 89 77 42 21 Fax: (44-14) 89 77 42 51 Email: lastrag@fdah.com	Fort Dodge Animal Health Limited	Suvaxyn Parvo/E	Emulsion for injection	— PPV inducing a HIA titre of at least 160 (in rabbits). — E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
Spain	Fort Dodge Veterinaria S.A. Ctra. Camprodón s/n 'La Riba' E-17813 Vall de Bianya (Girona) Tel: (34) 915 98 13 36 Fax: (34) 915 97 24 34 Email: rodrigv2@fdah.com	Fort Dodge Veterinaria S.A.	Suvaxyn Parvo/E	Emulsion for injection	— PPV inducing a HIA titre of at least 160 (in rabbits). — E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml

ANNEX VI

NAME, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ANIMAL SPECIES, ROUTES OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDER

Member State	Marketing Authorisation Holder	Applicant	Product invented name	Pharmaceutical form	Strength	Animal species	Frequency and route of administration	Recommended dose
Austria	Wyeth Lederle Pharma GmbH, Fort Dodge Waidhausengasse 19/9 A-1140 Vienna Contact: Dr. Attila Romváry Tel: (43-1) 912 28 40 Fax: (43-1) 911 51 00 Email: romvara@fdah.com	Wyeth Lederle Pharma GmbH, Fort Dodge	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
Belgium	Fort Dodge Animal Health Benelux B.V. Van Houten Industriepark 25 1381 MZ Weesp The Netherlands Contact: Dr. Durk Stellingwerf Tel: (31-35) 699 33 72 Fax: (31-35) 699 33 80 Email: stellid@fdah.com	Fort Dodge Animal Health Benelux B.V.	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
Czech Republic	Fort Dodge Animal Health Holland C.J van Houtenlaan 36 1381 CP Weesp The Netherlands Contact: Dr. Durk Stellingwerf Tel: (31-35) 699 33 72 Fax: (31-35) 699 33 80 Email: stellid@fdah.com	Fort Dodge Animal Health Holland	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml

Member State	Marketing Authorisation Holder	Applicant	Product invented name	Pharmaceutical form	Strength	Animal species	Frequency and route of administration	Recommended dose
Estonia	Fort Dodge Animal Health Holland C.J van Houtenlaan 36 1381 CP Weesp The Netherlands Contact: Dr. Durk Stellingwerf Tel: (31-35) 699 33 72 Fax: (31-35) 699 33 80 Email: stellid@fdah.com	Fort Dodge Animal Health Holland	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
France	Fort Dodge Santé Animale S.A. 24, Avenue Marcel Dassault BP 440 F-37204 Tours Cedex 3 Contact: Mr. Yves Dehon Tel: +33 2 47 74 89 79 Fax: +33 2 47 74 89 71 Email: dehonyv@fdah.com	Fort Dodge Santé Animale S.A.	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
Germany	Fort Dodge Veterinär GmbH Adenauerstrasse 20 D-52146 Würselen Contact: Dr. Elisabeth Stangl Tel: (49-240) 545 42 16 Fax: (49 24) 545 44 61 Email: stangle@fdah.com	Fort Dodge Veterinär GmbH	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml

Member State	Marketing Authorisation Holder	Applicant	Product invented name	Pharmaceutical form	Strength	Animal species	Frequency and route of administration	Recommended dose
Greece	Fort Dodge Animal Health Holland C.J van Houtenlaan 36 1381 CP Weesp The Netherlands Contact: Dr. Germán Lastra Tel: (44-14) 89 77 42 21 Fax: (44-14) 89 77 42 51 Email: lastrag@fdah.com	Fort Dodge Animal Health Holland	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
Ireland	Fort Dodge Animal Health Limited Flanders Road Hedge End Southampton S030 4QH United Kingdom Contact: Dr. Germán Lastra Tel: (44-14) 89 77 42 21 Fax: (44-14) 89 77 42 51 Email: lastrag@fdah.com	Fort Dodge Animal Health Limited	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
Italy	Fort Dodge Animal Health SpA Via Nettunense 90 I-04011 Aprilia Tel: (39-06) 927 151 Fax: (39-06) 23 32 55 55 Email: bollaa@fdah.com	Fort Dodge Animal Health SpA	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml

Member State	Marketing Authorisation Holder	Applicant	Product invented name	Pharmaceutical form	Strength	Animal species	Frequency and route of administration	Recommended dose
Lithuania	Fort Dodge Animal Health Holland C.J van Houtenlaan 36 1381 CP Weesp The Netherlands Contact: Dr. Durk Stellingwerf Tel: (31-35) 699 33 72 Fax: (31-35) 699 33 80 Email: stellid@fdah.com	Fort Dodge Animal Health Holland	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
Luxembourg	Fort Dodge Animal Health Benelux B.V. Van Houten Industriepark 25 1381 MZ Weesp The Netherlands Contact: Dr. Durk Stellingwerf Tel: (31-35) 699 33 72 Fax: (31-35) 699 33 80 Email: stellid@fdah.com	Fort Dodge Animal Health Benelux B.V.	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
Malta	Fort Dodge Animal Health Holland C.J van Houtenlaan 36 1381 CP Weesp The Netherlands Contact: Dr. Durk Stellingwerf Tel: (31-35) 699 33 72 Fax: (31-35) 699 33 80 Email: stellid@fdah.com	Fort Dodge Animal Health Holland	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml

Member State	Marketing Authorisation Holder	Applicant	Product invented name	Pharmaceutical form	Strength	Animal species	Frequency and route of administration	Recommended dose
Netherlands	Fort Dodge Animal Health Benelux B.V. Van Houten Industriepark 25 1381 MZ Weesp The Netherlands Contact: Dr. Durk Stellingwerf Tel: (31-35) 699 33 72 Fax: (31-35) 699 33 80 Email: stellid@fdah.com	Fort Dodge Animal Health Benelux B.V.	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
Norway	Fort Dodge Veterinär GmbH Adenauerstrasse 20 D-52146 Würselen Contact: Dr. Germán Lastra Tel: (44-14) 89 77 42 21 Fax: (44-14) 89 77 42 51 Email: lastrag@fdah.com	Fort Dodge Veterinär GmbH	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
Portugal	Fort Dodge Veterinària Lda. Rua Dr. António Loureiro Borges, n.º 2, Arquiparque-Miraflores P-1495-131 Algés Contact: Dr. Virginia Rodríguez Tel: (34-91) 598 13 43 Fax: (34-91) 597 24 34 Email: rodrigv2@fdah.com	Fort Dodge Veterinària Lda.	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml

Member State	Marketing Authorisation Holder	Applicant	Product invented name	Pharmaceutical form	Strength	Animal species	Frequency and route of administration	Recommended dose
Slovak Republic	Fort Dodge Animal Health Holland C.J van Houtenlaan 36 1381 CP Weesp The Netherlands Contact: Dr. Durk Stellingwerf Tel: (31-35) 699 33 72 Fax: (31-35) 699 33 80 Email: stellid@fdah.com	Fort Dodge Animal Health Holland	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
United Kingdom	Fort Dodge Animal Health Limited Flanders Road Hedge End Southampton S030 4QH United Kingdom Contact: Dr. Germán Lastra Tel: (44-14) 89 77 42 21 Fax: (44-14) 89 77 42 51 Email: lastrag@fdah.com	Fort Dodge Animal Health Limited	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml
Hungary	Fort Dodge Animal Health Holland C.J van Houtenlaan 36 1381 CP Weesp The Netherlands Contact: Dr. Durk Stellingwerf Tel: (31-35) 699 33 72 Fax: (31-35) 699 33 80 Email: stellid@fdah.com	Fort Dodge Animal Health Holland	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml

Member State	Marketing Authorisation Holder	Applicant	Product invented name	Pharmaceutical form	Strength	Animal species	Frequency and route of administration	Recommended dose
Spain	Fort Dodge Veterinaria, S.A. Ctra. Camprodón s/n 'La Riba' E-17813 Vall de Bianya (Girona) Contact: Dra Virginia Rodríguez Tel: (34-91) 598 13 36 Fax: (34-91) 597 24 34 Email: rodrigv2@fdah.com	Fort Dodge Veterinaria, S.A.	Suvaxyn Ery	Emulsion for injection	— E. rhusiopathiae: RP ≥ 1 in accordance with the EP	Porcine	From 5 months: 2 inj. 3-4 wks apart. 2nd dose at least 4 wks before mating. Annual Revacc-ination: 1 dose during each lacta-tion period 3 to 4 wks before mating. Intramuscular injection	2 ml

ANNEX VII

NAME, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ANIMAL SPECIES, ROUTES OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDER

Member State	Applicant or Marketing Authorisation Holder	Product invented name	Pharmaceutical form	Strength	Animal species	Frequency and route of administration	Recommended dose
Netherlands, Austria, Belgium, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, Norway, Poland, Portugal and Spain	Le Vet B.V. The Netherlands	Equimectine	Oral gel	12 mg/g	Horses	Oral use. A single administration of 0.2 mg ivermectin per kg of bodyweight. Retreatment should be done according to the epidemiological situation, but not at less than 30 days interval	A single administration of 0.2 mg ivermectin per kg of bodyweight

ANNEX VIII

LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

Member State	Marketing Authorisation Holder	Applicant	Invented name	Strength	Pharmaceutical Form	Route of administration
Denmark	Sandoz Pharmaceuticals GmbH Carl-Zeiss-Ring 3 D-85737 Ismaning		Mefecur	50/5 mg	Prolonged-release tablet	oral
Germany		Sandoz Pharmaceuticals GmbH Carl-Zeiss-Ring 3 D-85737 Ismaning	Felodipin Metoprolol Sandoz 5 mg/47,5 mg Retardtabletten	50/5 mg	Prolonged-release tablet	oral

ANNEX IX

LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

Member State	Marketing Authorisation Holder	Applicant	Invented name	Strength	Pharmaceutical Form	Route of administration
Denmark	ratiopharm GmbH Graf-Arco-Str. 3 D-89079 Ulm		Mefecomb 50 mg/5 mg	50/5 mg	Prolonged-release tablet	oral
Germany		ratiopharm GmbH Graf-Arco-Str. 3 D-89079 Ulm	Metoprololtartrat/Felodipin-ratiopharm 50 mg/5 mg Retardtabletten	50/5 mg	Prolonged-release tablet	oral
Finland		ratiopharm GmbH Graf-Arco-Str. 3 D-89079 Ulm	Mefecomb 50 mg/5 mg depot-tabletti	50/5 mg	Prolonged-release tablet	oral
Luxembourg		ratiopharm GmbH Graf-Arco-Str. 3 D-89079 Ulm	Metoprololtartrat/Felodipin-ratiopharm 50 mg/5 mg Retardtabletten	50/5 mg	Prolonged-release tablet	oral

ANNEX X

LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

Member State	Marketing Authorisation Holder	Applicant	Invented name	Strength	Pharmaceutical Form	Route of administration
Denmark	ratiopharm GmbH Graf-Arco-Str. 3 D-89079 Ulm		Mefelor	50/5 mg	Prolonged-release tablet	oral
Germany		AbZ-Pharma GmbH Dr.-Georg-Spohn-Str. 7 D-89143 Blaubeuren	Metoprololtartrat/Felodipin AbZ 50 mg/5 mg Retardtabletten	50/5 mg	Prolonged-release tablet	oral

ANNEX XI

LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

Member State	Marketing Authorisation Holder	Applicant	Invented name	Strength	Pharmaceutical Form	Route of administration
Denmark	CT Arzneimittel GmbH Lengeder Str. 42a D-13407 Berlin		Mefesan	50/5 mg	Prolonged-release tablet	oral
Germany		CT Arzneimittel GmbH Lengeder Str. 42a D-13407 Berlin	Metoprololtartrat/Felodipin-CT 50 mg/5 mg Retardtabletten	50/5 mg	Prolonged-release tablet	oral

ANNEX XII

LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

Member State	Marketing Authorisation Holder	Applicant	Invented name	Strength	Pharmaceutical Form	Route of administration
Denmark	YES Pharmaceutical Development Services GmbH Bahnstraße 42-46 D-61381 Friedrichsdorf		Metofelosan	50/5 mg	Prolonged-release tablet	oral
Germany		ALIUD PHARMA GmbH & Co. KG Gottlieb-Daimler-Str. 19 D-89150 Laichingen	Metocomb AL 50 mg/5 mg Retardtabletten	50/5 mg	Prolonged-release tablet	oral

ANNEX XIII

LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES

Member State	Marketing Authorisation Holder	Applicant	Invented name	Strength	Pharmaceutical Form	Route of administration
Denmark	YES Pharmaceutical Development Services GmbH Bahnstraße 42-46 D-61381 Friedrichsdorf		Metoprolol/Felodipin 'YES'	50/5 mg	Prolonged-release tablet	oral
Belgium		Eurogenerics N.V. Heizel Esplanade Heysel b22 B-1020 Brussels	Co-Metoprolol EG 50/5 mg tablets (prolonged release)	50/5 mg	Prolonged-release tablet	oral
Germany		STADApharm GmbH Stadastr. 2-18 D-61118 Bad Vilbel	Metoplus STADA 50 mg/5 mg Retardta-bletten	50/5 mg	Prolonged-release tablet	oral
Finland		STADA Arzneimittel AG Stadastr. 2-18 D-61118 Bad Vilbel	Metoprololitartraatti/Felodipiini STADA 50 mg/5 mg depottabletti	50/5 mg	Prolonged-release tablet	oral
Luxembourg		Eurogenerics N.V. Heizel Esplanade Heysel b22 B-1020 Brussels	Co-Metoprolol EG 50/5 mg tablets (prolonged release)	50/5 mg	Prolonged-release tablet	oral

Opinion of the Advisory Committee on Concentrations given at its 137th meeting on 1 March 2006 concerning a draft decision relating to Case COMP/M.3868 — DONG/Elsam/Energy E2

Rapporteur: Hungary

(2007/C 115/05)

1. The Advisory Committee agrees with the Commission that the notified operation constitutes a concentration within the meaning of Article 3(1)(b) of Council Regulation (EC) No 139/2004 [1] and that it has a Community dimension.

2. The Advisory Committee agrees with the Commission that for the purposes of assessing the present operation, the **relevant product markets** are:

in the natural gas sector:

a) the market for storage or alternatively the market for flexibility of natural gas;

b) the wholesale market of natural gas;

c) the market for the supply of natural gas to central combined heat and power plants (CHPs);

d) the market or markets for the supply of natural gas to large industrial customers and to decentralized CHPs;

e) the market or markets for the supply of natural gas to non-metered small business customers and to households;

in the electricity sector:

f) the wholesale market of electricity (irrespective of whether it includes or not bilateral wholesales and ancillary services, constituting possibly separate markets),

g) the market for financial derivatives of electricity (irrespective of whether it includes or not CfDs constituting a possibly separate market) ,

h) the retail market for electricity sales to metered (business) customers,

i) the retail market for electricity sales to non-metered (predominantly household) customers;

for other markets:

j) the market for district heating,

k) the market for fly ash production,

l) the market for trading of CO_2 emission rights.

3. The Advisory Committee agrees with the Commission that for the purposes of assessing the present operation, the **relevant geographic markets** are:

in the natural gas sector:

a) the market for storage, or alternatively the Danish market for flexibility of natural gas, for Denmark is Danish;

b) the market for storage or alternatively the Swedish market for flexibility of natural gas for Sweden is Swedish or alternatively Swedish-Danish in scope;

c) the wholesale market for natural gas for Denmark is Danish in scope;

d) the wholesale market for natural gas for Sweden is Swedish or alternatively Swedish-Danish in scope;

[1] OJ L 24, 29.1.2004, p. 1.

e) the market for the supply of natural gas to Danish central CHPs is Danish;

f) the market for the supply of natural gas to Swedish central CHPs is Swedish or alternatively Swedish-Danish in scope;

g) the market or markets for the supply of natural gas to large industrial customers and to decentralized CHPs is Danish in scope);

h) the market or markets for the supply of natural gas to small business customers and to households is/are Danish-national or Danish-regional in scope;

in the electricity sector:

i) the wholesale market of electricity is East Danish and West Danish or wider; if ancillary services constitute one or more relevant markets then the geographic scope of such market(s) is East Danish and West Danish;

j) the market for financial derivatives of electricity encompasses the Nord Pool area if excluding CfDs; if CfDs constitute a separate market then the relevant markets are the individual NordPool areas, i.e. East Danish and West Danish;

k) the retail market for electricity sales to metered (business) customers is Danish in scope;

l) the retail market for electricity sales to non-metered (predominantly household) customers is Danish-national or Danish-regional in scope;

for other markets:

m) the market for district heating is local;

n) the scope of the geographic market for fly ash production can be left open;

o) the market for CO_2 trading is EU-wide.

4. The Advisory Committee agrees with the Commission that DONG has a dominant position:

in the natural gas sector:

a) on the market for gas storage or gas flexibility for Denmark;

b) on the wholesale market of natural gas for Denmark;

c) on the market or markets for the supply of natural gas to large industrial customers and decentralised CHPs in Denmark;

d) on the market or markets for the supply of natural gas to small business customers and/or households on two of the five Danish regional areas (single dominance) or alternatively on a national market with HNG/MN? (joint dominance),

e) and that the question for the markets for gas storage or gas flexibility and gas wholesale for Sweden can remain open as any commitments which are sufficient to remedy the competition concerns on the respective markets for Denmark also solve such problems on the markets for Sweden.

5. The Advisory Committee agrees with the Commission that the transaction will give DONG the ability and incentive on the Danish gas storage or gas flexibility market to raise rivals' costs of storage post merger, increase storage tariffs in Denmark and to use the central CHP plants owned by Elsam and Energi E2 for flexibility purposes and that the transaction would thus strengthen DONG's dominant position on the possible Danish market for storage or on the possible Danish market for storage/flexibility and would lead to a significant impediment to effective competition.

6. The Advisory Committee agrees with the Commission that the transaction will strengthen DONG's dominant position on the Danish wholesale market especially through removing significant actual and potential competitive constraints to DONG and through foreclosure of demand and that this is likely to lead to a significant impediment to effective competition.

7. The Advisory Committee agrees with the Commission that the concentration does not lead to a significant impediment of effective competition on the markets for natural gas supplies to central CHPs either in Denmark or in Sweden.

8. The Advisory Committee agrees with the Commission that the concentration will lead to a significant impediment of effective competition on the market or markets of the supply of natural gas to large industrial customers and decentralised CHPs especially through raising entry barriers and eliminating potential competition.

9. The Advisory Committee agrees with the Commission that the concentration will significantly impede competition on the market or markets for the supply of natural gas to households and small business customers irrespective of whether these markets are defined as regional or as national in particular through the strengthening of a dominant position.

10. The Advisory Committee agrees with the Commission that the notified concentration does not lead to a significant impediment of effective competition, in particular as a result of the creation or strengthening of a dominant position on either any possible affected market for physical electricity or for financial derivatives of electricity.

11. The Advisory Committee agrees with the Commission that in the absence of competition concerns it is not necessary to examine further the effect of the concentration on the markets for district heating, fly ash production and CO2 trading.

12. The majority of the Advisory Committee agrees with the Commission that the commitments submitted by the parties concerning storage divestiture and the gas release programme are suitable and in combination with each other sufficient to remove the identified competition problems on the following markets:

    a) market for gas storage or gas flexibility irrespective of whether only for Denmark or also for Sweden;

    b) the wholesale markets of natural gas for Denmark and potentially also for Sweden;

    c) the market or markets for the supply of natural gas to large industrial customers and/or decentralised CHPs in Denmark;

    d) the market or markets for supply of natural gas to small business customers and/or households in Denmark.

    A minority disagrees with point b).

13. The Advisory Committee agrees with the Commission that, subject to full compliance with the commitments offered by the parties the proposed concentration does not significantly impede effective competition and as a result the proposed concentration can be declared compatible with the common market and the functioning of the EEA Agreement.

14. The Advisory Committee asks the Commission to take into account all the other points raised during the discussion.

Final report of the Hearing Officer in Case COMP/M.3868 — Dong/Elsam/Energi E2

(pursuant to Article 15 of Commission Decision (2001/462/EC, ECSC) of 23 May 2001 on the terms of reference of Hearing Officers in certain competition proceedings — OJ L 162, 19.6.2001, p. 21)

(2007/C 115/06)

The proposed concentration

On 13 September 2005, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ([1]) ('the Merger Regulation') whereby the Danish gas incumbent DONG acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of two important Danish power generators (Elsam in the West; Energi E2 in the East) and of two electricity distribution companies, namely København Energi and Frederiksberg Elnet (the latter four companies are hereinafter referred to as 'other involved parties').

The initiation of proceedings and provision of key documents

At the end of the first phase of the investigation, the Commission concluded that the concentration raised serious doubts as to its compatibility with the common market and with the EEA Agreement. On 18 October 2005, the Commission therefore initiated proceedings in accordance with Article 6(1)(c) of the Merger Regulation.

On 7 November 2005 DONG was provided with access to the 'key documents' in the Commission file in accordance with chapter 7.2. of the 'Best Practices on the conduct of EC merger control proceedings' ('Best Practices'), as determined by the Directorate General for Competition.

The Statement of Objections and the parties' reply

A Statement of Objections was sent to DONG on 19 December 2005. The other involved parties were provided with a non-confidential version of these objections. In the following days, access to the Commission's file was granted. DONG was asked to reply by 9 January 2006. DONG and the other involved parties submitted a joint reply on 5 January 2006.

In their reply of 5 January 2006, DONG considered that 'their ability to respond to the Commission's concerns in the SO had been undermined by the Commission's approach to the provision on access to file'. More specifically, they stated that 'the level of redaction of third party submissions was not satisfactory and made it difficult for the parties to properly scrutinise or assess the documents'. By letter of 16 January 2006, I informed DONG that subsequent to Article 8 of Commission Decision 2001/462/EC, ECSC of 23 May 2001 on the terms of reference of hearing officers in certain competition proceedings ([2]), they were entitled to lodge a reasoned request for access to file with me should they consider that they had not received the information they were entitled to in order to prepare their defence. DONG has not reacted to my letter.

Neither DONG, nor the other involved parties requested to develop their arguments in a formal oral hearing.

The participation of a third party

Upon request, I admitted Naturgas Fyn Group as a third party according to Article 18(4) of Council Regulation 139/2004 on 22 December 2005. They were sent a non-confidential version of the Statement of Objections.

The commitments and the results of the market test

On 30 January 2006, DONG offered commitments. The results of the market test of these commitments conducted as from 1 February 2006 were mixed. Concerns were raised in particular with regard to the effectiveness of the two-step auction process provided for in the envisaged Gas Release Programme. As a result, the commitments were amended. I have not been asked to verify the objectivity of the enquiry.

([1]) OJ L 24, 29.1.2004, p. 1.
([2]) OJ L 162, 19.6.2001, p. 21.

The draft decision and the respect of the right to be heard

In the light of the commitments proposed and having analysed the results of the market test, the draft decision concludes that the proposed concentration is compatible with the common market and with the EEA Agreement.

In the light of the above, I consider that the rights to be heard of all participants to the present proceeding have been respected.

Brussels, 21 February 2006

Serge DURANDE

NOTICES FROM MEMBER STATES

Information communicated by Member States regarding State aid granted under Commission Regulation (EC) No 68/2001 on the application of Articles 87 and 88 of the EC Treaty to training aid

(Text with EEA relevance)

(2007/C 115/07)

Aid No	XT 3/07		
Member State	Cyprus		
Region	Κύπρος (Kypros)		
Title (and/or name of the beneficiary)	Μονοεπιχειρησιακά Προγράμματα Συνεχιζόμενης Κατάρτισης στην Κύπρο [Τίτλος και αριθμός της υφιστάμενης ενίσχυσης: Αρχή Ανάπτυξης Ανθρώπινου Δυναμικού — Μονοεπιχειρησιακά προγράμματα συνεχιζόμενης κατάρτισης — Συνήθη (CY 12/2002)]		
Legal basis	Ο περί Ανάπτυξης Ανθρωπίνου Δυναμικού Νόμος [Νόμος 125(I) του 1999, άρθρο 21)]		
Annual expenditure planned or overall amount of aid granted to the company	Aid scheme	Annual overall amount	CYP 2,5 million
		Loans guaranteed	—
	Individual aid	Overall aid amount	—
		Loans guaranteed	—
Maximum aid intensity	Under Article 4(2)-(7) of the Regulation		Yes For general training: — 50 % for large enterprises — 70 % for micro, small and medium-sized enterprises. For specific training: — 25 % for large enterprises — 35 % for micro, small and medium-sized enterprises.
Date of implementation	1.1.2007		
Duration of scheme or individual aid award	Until 30.6.2008		
Objective	General training		Yes Documentary evidence confirming the general nature of the training provided was attached to the notification of the existing scheme.
	Specific training		Yes

Economic sectors	All sectors eligible for training aid	Yes
Name and address of the granting authority	Αρχή Ανάπτυξης Ανθρώπινου Δυναμικού Κύπρου Αναβύσσου 2 Στρόβολος, Τ.Θ. 25431 CY-1392 Λευκωσία	
Large individual aid grants	In conformity with Article 5 of the Regulation This State aid scheme does not provide for large individual aid grants.	Yes

Reference number of the aid	XT 4/07	
Member State	Cyprus	
Region	Κύπρος (Kypros)	
Title (and/or name of the beneficiary)	Μονοεπιχειρησιακά Προγράμματα Συνεχιζόμενης Κατάρτισης στο Εξωτερικό [Τίτλος και αριθμός υφιστάμενης ενίσχυσης: Αρχή Ανάπτυξης Ανθρώπινου Δυναμικού — Μονοεπιχειρησιακά προγράμματα συνεχιζόμενης κατάρτισης στο εξωτερικό (CY 11/2002)]	
Legal basis	Ο περί Ανάπτυξης Ανθρωπίνου Δυναμικού Νόμος [Νόμος 125(I) του 1999, άρθρο 21]	
Type of measure	Aid scheme	
Budget	Annual budget: CYP 0,6 million; Overall budget: —	
Maximum aid intensity	In conformity with Article 4(2)-(7) of the Regulation	Yes For general training: — 50 % for large enterprises — 70 % for micro, small and medium-sized enterprises. For specific training: — 25 % for large enterprises — 35 % for micro, small and medium-sized enterprises.
Date of implementation	1.1.2007	
Duration	30.6.2008	
Objective	General training; Specific training	Yes Documentary evidence confirming the general nature of the training provided was attached to the notification of the existing scheme.
Economic sectors	All sectors eligible for training aid	
Name and address of the granting authority	Αρχή Ανάπτυξης Ανθρώπινου Δυναμικού Κύπρου Αναβύσσου 2 Στρόβολος, Τ.Θ. 25431 CY-1392 Λευκωσία	

Reference number of the aid	XT 5/07	
Member State	Cyprus	
Region	Κύπρος (Kypros)	
Title (and/or name of the beneficiary)	Μονοεπιχειρησιακά Προγράμματα Αρχικής Κατάρτισης [Τίτλος και αριθμός υφιστάμενης ενίσχυσης: Αρχή Ανάπτυξης Ανθρώπινου Δυναμικού — Μονοεπιχειρησιακά προγράμματα αρχικής κατάρτισης — Συνήθη (CY 13/2002)]	
Legal basis	Ο περί Ανάπτυξης Ανθρωπίνου Δυναμικού Νόμος [Νόμος 125(I) του 1999, άρθρο 21]	
Type of measure	Aid scheme	
Budget	Annual budget: CYP 0,01 million; Overall budget: —	
Maximum aid intensity	In conformity with Article 4(2)-(7) of the Regulation	Yes For general training: — 50 % for large enterprises — 70 % for micro, small and medium-sized enterprises.
Date of implementation	1.1.2007	
Duration	30.6.2008	
Objective	General training	Yes Documentary evidence confirming the general nature of the training provided was attached to the notification of the existing scheme.
Economic sectors	All sectors eligible for training aid	
Name and address of the granting authority	Αρχή Ανάπτυξης Ανθρώπινου Δυναμικού Κύπρου Αναβύσσου 2 Στρόβολος, Τ.Θ. 25431 CY-1392 Λευκωσία	

V

(Announcements)

ADMINISTRATIVE PROCEDURES

COMMISSION

CALL FOR PROPOSALS DG EAC/20/07

(DIRECTORATE-GENERAL FOR EDUCATION AND CULTURE)

UNDER THE LIFELONG LEARNING PROGRAMME

Award of grants for actions to develop and test the European Qualifications Framework (EQF), including national and sectoral qualifications frameworks

(2007/C 115/08)

1. Objectives and description

The objective of this call for proposals is to award grants to approximately 10-15 proposals, with participants from the maximum number of countries and sectors, to organise actions to support consortia:

— to develop and test the principles and mechanisms of the future EQF

— to exchange experiences at national and sectoral level in using the EQF as a common reference point, including the development of qualifications frameworks and, for example, establishing closer links between the European Higher Education Area and the EQF.

2. Eligible applicants

The submission of applications for grants under this Call is open especially to consortia of European, national, regional and sectoral organisations, including, for example, ministries, qualifications authorities, sectoral associations, social partners and other key stakeholders with an interest and role in qualifications systems. Applicants should also have representative legitimacy in terms of the sector, labour market or education and training system(s) that their project is intended to benefit.

Applications for funding may only be made by consortia consisting of organisations drawn from 5 or more countries.

Applications may be submitted by organisations established in one of the following countries:

— the 27 EU Member States

— the three EFTA-EEA countries (Iceland, Liechtenstein, Norway) (*)

— Turkey (*)

(*) Agreements establishing the participation of these countries are currently being finalised and are expected to enter into force by the date of selection. Updated information can be accessed at: http://eacea.ec.europa.eu/static/en/llp/funding_en.htm#update

3. **Budget and project duration**

The total budget earmarked for the cofinancing of projects amounts to EUR 2 million. Financial assistance from the Commission cannot exceed 75 % of the total eligible costs.

Grants are expected to be between EUR 50 000 and EUR 200 000.

Activities must start not later than mid-February 2008. The maximum duration of projects is 24 months.

4. **Deadline**

Applications must be despatched, date as postmark, to the Education, Audiovisual and Culture Executive Agency no later than 31 August 2007.

5. **Further information**

The full text of the call for proposals and the application forms are available on the following website:

http://ec.europa.eu/dgs/education_culture/calls/grants_en.html

Applications must comply with the requirements set out in the full text and be submitted using the form provided.

Call for proposals under the draft annual work programme for grants in the field of the Trans-European Transport Network (TEN-T) for 2007 (Commission Decision C(2007) 2183)

(2007/C 115/09)

The European Commission, Directorate-General for Energy and Transport, is hereby launching a call for proposals in order to award grants to projects in accordance with the priorities and objectives defined in the draft annual work programme for grants in the field of the Trans-European Transport Network for 2007.

The maximum amount available under this call for proposals, for 2007, is EUR 112 607 450.

The call is closing on 20 July 2007.

The complete text of the Call for proposals is available on:

http://ec.europa.eu/dgs/energy_transport/grants/proposal_en.htm

Call for proposals under the draft multi-annual work programme for grants in the field of the Trans-European Transport Network (TEN-T) for the period 2007-2013 (Commission Decision C(2007) 2158)

(2007/C 115/10)

The European Commission, Directorate-General for Energy and Transport is hereby launching a call for proposals, under the draft multi-annual work programme for the Trans-European Transport Network (TEN-T) for the period 2007-2013, in order to award grants to:

Field No 1:

TEN-T Priority Projects included in annex III of the Community Guidelines for the development of a trans-European transport network (Decision of the European Parliament and the Council No 1692/96/EC , as last modified by Council Decision (EC) No 1791/2006). The maximum amount available for the selected proposals, for the period 2007-2013, shall range from EUR 4,9004 to 5,30105 billion.

Field No 2:

projects in the field of Intelligent transport systems, sector of Air Traffic Management (ATM)/SESAR. The maximum total amount available for the selected proposals, for the period 2007-2013, is EUR 350 million.

Field No 3:

projects in the field of Intelligent Transport Systems for road traffic (ITS road). The maximum total amount available for the selected proposals, for 2007, is EUR 100 million.

Field No 4:

projects in the field of European Rail Traffic Management System (ERTMS). The maximum total amount available for the selected proposals, for 2007, is EUR 250 million.

The call is closing on 20 July 2007.

The complete text of the Call for proposals is available on:

http://ec.europa.eu/dgs/energy_transport/grants/proposal_en.htm

Calls for proposals under the work programme for 2007 of the Information and Communication Technologies Policy Support Programme as part of the Competitiveness and Innovation Framework Programme (2007 to 2013)

(2007/C 115/11)

Notice is hereby given of the launch of the call for proposals under the work programme for 2007 of the Information and Communication Technologies Policy Support Programme (ICT PSP) as part of the Competitiveness and Innovation Framework Programme — (2007 to 2013).

Proposals are invited for the following call: CIP-ICT PSP-2007-1

Call documentation including content, deadline and budget is given in the call texts which are published on the ICT PSP website:

http://ec.europa.eu/ict_psp

PROCEDURES RELATING TO THE IMPLEMENTATION OF THE COMPETITION POLICY

COMMISSION

Prior notification of a concentration

(Case COMP/M.4689 — Wingas/HydroWingas)

Candidate case for simplified procedure

(Text with EEA relevance)

(2007/C 115/12)

1. On 15 May 2007, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 ([1]) by which the undertaking Wingas GmbH ('Wingas', Germany), controlled by Wintershall Holding AG ('Wintershall', Germany) and belonging to the BASF Group, acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of the undertaking HydroWingas Limited ('HydroWingas', UK), currently jointly controlled by Wingas and Norsk Hydro (UK) Limited, by way of purchase of shares.

2. The business activities of the undertakings concerned are:

— for Wingas: supply, transportation and storage of natural gas;

— for Wintershall: exploration, production and sale of crude oil and natural gas;

— for HydroWingas: supply and trading of natural gas in the UK.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 ([2]) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax ((32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4689 — Wingas/HydroWingas, to the following address:

European Commission
Directorate-General for Competition
Merger Registry
J-70
B-1049 Bruxelles/Brussel

([1]) OJ L 24, 29.1.2004, p. 1.
([2]) OJ C 56, 5.3.2005, p. 32.